Lucia Silla

Lucia Silla

Auto-generated profile, based on publicly available information

Lucia Silla

Hospital de Clínicas de Porto Alegre

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LSLucia Silla
Lucia Silla
VVVanessa Valim
Vanessa Valim
APAnnelise Pezzi
Annelise Pezzi
MSMaria da Silva
Maria da Silva
IWIanae Wilke
Ianae Wilke
DLDean Lee
Dean Lee

25 August 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
MCMaria A. A. Clavijo-Salomon
Maria A. A. Clavijo-Salomon
RSRosalba Salcedo
Rosalba Salcedo
SRSoumen Roy
Soumen Roy
RNRodrigo X. das Neves
Rodrigo X. das Neves
ADAmiran Dzutsev
Amiran Dzutsev
GTGiorgio Trinchieri
Giorgio Trinchieri
Adaptive immune responses are acknowledged to evolve from innate immunity. However, limited information exists regarding whether encounters between innate cells direct the generation of specialized T-cell subsets. We aim to understand how natural killer (NK) cells modulate cell-mediated immunity in humans. We found that human CD14+CD16− monocytes that differentiate into inflammatory dendritic cells (DCs) are shaped at the early stages of differentiation by cell-to-cell interactions with NK cells. Although a fraction of monocytes is eliminated by NK-cell–mediated cytotoxicity, the polarization of interferon-γ (IFN-γ) at the NKp30-stabilized synapses triggers a stable IFN-γ signature in surviving monocytes that persists after their differentiation into DCs. Notably, NK-cell–instructed DCs drive the priming of type 17 CD8+ T cells (Tc17) with the capacity to produce IFN-γ and interleukin-17A. Compared with healthy donors, this cellular network is impaired in patients with classical NK-cell deficiency driven by mutations in the GATA2 gene. Our findings reveal a previously unrecognized connection by which Tc17-mediated immunity might be regulated by NK-cell–mediated tuning of antigen-presenting cells.

12 December 2013 in Bone Marrow Research
Verified
Journal Article
Open access
PDF file
BPBeatriz Stela Pitombeira
Beatriz Stela Pitombeira
APAlessandra Paz
Alessandra Paz
APAnnelise Pezzi
Annelise Pezzi
BABruna Amorin
Bruna Amorin
VVVanessa Valim
Vanessa Valim
LSLucia Silla
Lucia Silla
Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at http://dx.doi.org/10.13039/501100003810 Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P<0.001), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P=0.001). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil.

9 April 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
BKBridget A. Kennis
Bridget A. Kennis
KMKeith A. Michel
Keith A. Michel
WBWilliam B. Brugmann
William B. Brugmann
ALAlvaro Laureano
Alvaro Laureano
RTRong-Hua Tao
Rong-Hua Tao
VGVidya Gopalakrishnan
Vidya Gopalakrishnan
There was a typo in author Andrew Wahba’s name in the initial online publication. The original article has been corrected.

24 July 2024 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
CSCinthya Corrêa Da Silva
Cinthya Corrêa Da Silva
ASAnderson João Simione
Anderson João Simione
PSPaula Moreira da Silva Sabaini
Paula Moreira da Silva Sabaini
AMAntonio Vaz Macedo
Antonio Vaz Macedo
HNHeliz Regina Alves das Neves
Heliz Regina Alves das Neves
FDFernando Barroso Duarte
Fernando Barroso Duarte
Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved for standard of care treatment of patients with lymphoma and leukemia worldwide. Here we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 38 patients who received CAR T cells between 2020 and 2023. The median age was 47 years (range 4-77). Indications include Non-Hodgkin Lymphoma (NHL; 26 cases; 68%), Acute Lymphoblastic Leukemia (ALL; 9 cases; 24%), and Multiple Myeloma (MM; 3 cases; 8%). 84% (75% - 24 NHL cases and 25% - 8 ALL cases) were commercial. This report demonstrates the initial implementation of CAR T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.

9 July 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
LSLúcia Silla
Lúcia Silla
SARS‐CoV‐2, affecting predominantly elderlies, was recognized as a global pandemic in March 11th, 2020; clinical signs and laboratory alterations are similar to previous coronavirus epidemics with lymphocytopenia and neutrophilia observed in severe cases.